Definium Therapeutics
DFTX
362 hedge funds and large institutions have $5.35B invested in Definium Therapeutics in 2026 Q2 according to their latest regulatory filings, with 149 funds opening new positions, 117 increasing their positions, 64 reducing their positions, and 29 closing their positions.
414% more first-time investments, than exits
New positions opened: 149 | Existing positions closed: 29
263% more capital invested
Capital invested by funds: $1.47B → $5.35B (+$3.88B)
146% more call options, than puts
Call options by funds: $176M | Put options by funds: $71.4M
117% more funds holding in top 10
Funds holding in top 10: 6 → 13 (+7)
83% more repeat investments, than reductions
Existing positions increased: 117 | Existing positions reduced: 64
47% more funds holding
Funds holding: 247 → 362 (+115)
26.99% more ownership
Funds ownership: 78.29% → 105.28% (+27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$133M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$113M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$73.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$72.7M |
| 5 |
BlackRock
New York
|
+$68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
-$32.9M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$25.5M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$16.8M |
| 4 |
Millennium Management
New York
|
-$14.4M |
| 5 |
CCM
Catalio Capital Management
New York
|
-$11.7M |
DFTX Hedge Fund Activity: Q2 2026 in Review
362 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2026, worth a combined $5.35B — up 263% from $1.47B a quarter earlier.
Buyers outnumbered sellers: 149 funds opened new DFTX positions and 29 closed out — a net gain of 120 holders — while 117 added to existing stakes and 64 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $133M. The largest seller was Trails Edge Capital Partners, exiting entirely with an estimated $32.9M sold.
- 362 institutional investors held Definium Therapeutics (DFTX) as of Q2 2026, up from 247 in Q1 2026.
- Funds reported $5.35B of Definium Therapeutics stock for Q2 2026, up 263% quarter-over-quarter.
- 149 funds opened new Definium Therapeutics positions in Q2 2026 and 29 closed out, a net change of +120 holders.
- The largest Definium Therapeutics buyer in Q2 2026 was Capital World Investors, an estimated $133M added.
- The largest Definium Therapeutics seller in Q2 2026 was Trails Edge Capital Partners, an estimated $32.9M sold.
Based on aggregated 13F filings for Q2 2026.